Page last updated: 2024-11-06

broxaterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

broxaterol: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71149
CHEMBL ID2105475
SCHEMBL ID82745
MeSH IDM0133294

Synonyms (35)

Synonym
broxaterol
z-1170 ,
summair
broxaterol [inn]
3-bromo-alpha-(((1,1-dimethylethyl)amino)methyl)isoxazole-5-methanol
1-(3-brom-5-isoxazolyl)-2-tert-butylaminoethanol
einecs 278-494-4
(+-)-3-bromo-alpha-((tert-butylamino)methyl)-5-isoxazolemethanol
broxaterolum [latin]
c9h15brn2o2
z 1170
76596-57-1
ze4irb4duc ,
unii-ze4irb4duc
broxaterolum
nsc_71149
bdbm86449
cas_76596-57-1
CHEMBL2105475
SCHEMBL82745
AKOS022666091
broxaterol [mart.]
(+/-)-3-bromo-.alpha.-((tert-butylamino)methyl)-5-isoxazolemethanol
isoxazole, 3-bromo-5-[1-hydroxy-2-(t-butylamino)ethyl]-
1-(3-bromo-5-isoxazolyl)-2-(tert-butylamino)ethanol #
JBRBWHCVRGURBA-UHFFFAOYSA-N
Q4976876
Z1269230753
1-(3-bromoisoxazol-5-yl)-2-(tert-butylamino)ethanol
z 1170;z-1170;z1170
BCP20216
1-(3-bromo-1,2-oxazol-5-yl)-2-(tert-butylamino)ethan-1-ol
BB166952
DTXSID20868402
EN300-261807

Research Excerpts

Effects

ExcerptReferenceRelevance
"Broxaterol has been evaluated in 21 patients, 18 men and 3 women, aged 34 to 80 years, with a diagnosis of reversible obstructive airways disease."( Negligible metabolic effects of long-term oral treatment with a new beta 2-agonist: broxaterol.
Ansalone, D; Calvanese, RC; Federico, S; Galzerano, V; Gurrieri, G; Petraglia, A; Scarpitta, M; Zinno, A, 1990
)
1.22

Toxicity

ExcerptReferenceRelevance
" In long-term clinical evaluation, broxaterol has been shown to be well tolerated, with an incidence of adverse reactions equal to or less than that reported in the literature for other beta 2-agonists."( Broxaterol: therapeutic trials and safety profile.
Ziment, I, 1989
)
2

Bioavailability

ExcerptReferenceRelevance
" These findings account for a probably greater bioavailability of broxaterol after oral administration."( Broxaterol: pharmacological profile of a unique structural feature.
Della Bella, D, 1989
)
1.96

Dosage Studied

ExcerptRelevanceReference
" The PD20 (dose of histamine causing a 20% fall in FEV1) was measured before and 11, 35, and 59 h after cessation of treatment and a bronchodilator dose-response study before and 83 h after cessation of treatment."( Asthma control during and after cessation of regular beta 2-agonist treatment.
Pavord, ID; Tattersfield, AE; Wahedna, I; Wisniewski, AF; Wong, CS, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (33.33)18.7374
1990's23 (63.89)18.2507
2000's1 (2.78)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.33 (24.57)
Research Supply Index4.20 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials25 (60.98%)5.53%
Reviews3 (7.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (31.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]